On April 27, 2022 Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, reported that it will present data from the Phase 2 study of ADXS-503 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer and data from the Phase 1 study of ADXS-504 in patients with biochemically recurrent prostate cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held virtually, on June 3-7, 2022 (Press release, Advaxis, APR 27, 2022, View Source [SID1234613022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Abstract #1

Title: A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer either progressing on prior pembrolizumab or in the first line setting.
Session Type: Poster Session
Abstract Number: 9038
Date and Time: June 6, 2022, 8-11 AM (CDT)

Abstract #2

Title: Immunogenicity and disease control induced by a multi-neoantigen vaccine (ADXS-503) in patients with metastatic non-small cell lung cancer who have progressed on pembrolizumab.
Session Type: Poster Session
Abstract Number: 9042
Date and Time: June 6, 2022, 8-11 AM (CDT)

Abstract #3

Title: A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.

Session Type: Poster Session
Abstract Number: TPS5115
Date and Time: June 6, 2022, 1:15-4:15 CDT (CDT)